Castle Biosciences Exceeds 2025 Revenue Guidance with Strong Core Product Growth

summarizeResumen

The preliminary results indicate robust operational performance, with full-year 2025 revenue projected to surpass previous guidance. The substantial increase in test reports for core products like DecisionDx-Melanoma and TissueCypher, coupled with the successful limited launch of AdvanceAD-Tx, suggests strong market adoption and expansion opportunities. The healthy year-end cash position further strengthens the company's financial outlook for future growth initiatives.

check_boxEventos clave

• Exceeded Revenue Guidance

  2025 total revenue is expected to exceed $340 million, surpassing the previously guided range of $327-335 million.

• Strong Core Product Growth

  Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 37% for the full year 2025 and 42% in Q4 2025 year-over-year.

• TissueCypher Volume Surge

  TissueCypher Barrett's Esophagus test reports saw an 86% volume increase for the full year 2025 compared to 2024.

• New Product Launch

  AdvanceAD-Tx, a new test for atopic dermatitis, commenced a limited access launch in November 2025, with strong initial clinician adoption.

auto_awesomeAnalisis

The preliminary results indicate robust operational performance, with full-year 2025 revenue projected to surpass previous guidance. The substantial increase in test reports for core products like DecisionDx-Melanoma and TissueCypher, coupled with the successful limited launch of AdvanceAD-Tx, suggests strong market adoption and expansion opportunities. The healthy year-end cash position further strengthens the company's financial outlook for future growth initiatives.